Valuation: AbbVie Inc.

Market Cap 471B 414B 391B 355B 667B 45,169B 670B 4,686B 1,810B 23,049B 1,767B 1,728B 74,066B P/E 2026 *
33.7x
P/E 2027 * 25.1x
Enterprise Value 532B 468B 443B 401B 754B 51,081B 758B 5,299B 2,047B 26,066B 1,998B 1,955B 83,761B EV / Sales 2026 *
7.87x
EV / Sales 2027 * 7.12x
Free-Float
95.71%
Yield 2026 *
2.61%
Yield 2027 * 2.71%
1 day+32.99%
Current year-7.43%
Current year 176.4
Extreme 176.4
200.25
1 year 176.4
Extreme 176.4
200.25
3 years 164.86
Extreme 164.86
200.25
5 years 119.2
Extreme 119.2
200.25
10 years 119.2
Extreme 119.2
200.25
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO 59 2022-06-22
Chief Tech/Sci/R&D Officer - 2024-02-29
Director TitleAgeSince
Director/Board Member 65 2012-12-31
Director/Board Member 74 2012-12-31
Director/Board Member 69 2012-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+32.99%0.00% - - 471B
+0.11%+1.71%+63.52%+117.61% 1,056B
+0.27%+0.92%+51.33%+73.35% 655B
+0.73%+0.68%+20.70%+74.90% 471B
-0.70%-3.16%+37.68%+40.79% 342B
+0.09%+4.33%+22.67%+29.43% 277B
+1.55%+0.28%+14.61%+14.47% 257B
+0.85%+6.35%+53.17%+54.39% 226B
+0.85%+1.10%+35.78%+101.82% 189B
-0.10%-2.72%-28.38%-60.90% 170B
Average +3.57%+0.97%+30.12%+49.54% 404.77B
Weighted average by Cap. +3.83%+1.04%+40.45%+69.87%

Financials

2026 *2027 *
Net sales 67.6B 59.45B 56.22B 50.99B 95.77B 6,489B 96.32B 673B 260B 3,311B 254B 248B 10,640B 73.5B 64.64B 61.12B 55.44B 104B 7,055B 105B 732B 283B 3,600B 276B 270B 11,568B
Net income 14.07B 12.37B 11.7B 10.61B 19.93B 1,350B 20.04B 140B 54.1B 689B 52.81B 51.67B 2,214B 19.05B 16.75B 15.84B 14.37B 26.98B 1,828B 27.14B 190B 73.25B 933B 71.51B 69.96B 2,998B
Net Debt 61.59B 54.17B 51.23B 46.46B 87.26B 5,912B 87.76B 613B 237B 3,017B 231B 226B 9,695B 53.09B 46.69B 44.15B 40.05B 75.21B 5,096B 75.65B 529B 204B 2,601B 199B 195B 8,357B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
266.28USD
Average target price
278.61USD
Spread / Average Target
+4.63%

Quarterly revenue - Rate of surprise